Warning! GuruFocus detected
3 Severe warning signs
with HBI.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Harvard Bioscience Inc
NAICS : 334516
SIC : 3826
ISIN : US4169061052
Description
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.11 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.58 | |||||
| Debt-to-EBITDA | -13.53 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.7 | |||||
| Beneish M-Score | -2.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.8 | |||||
| 3-Year EPS without NRI Growth Rate | -192.8 | |||||
| 3-Year FCF Growth Rate | -175.9 | |||||
| 3-Year Book Growth Rate | -10.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 6.98 | |||||
| 9-Day RSI | 8.78 | |||||
| 14-Day RSI | 11.7 | |||||
| 3-1 Month Momentum % | -40.95 | |||||
| 6-1 Month Momentum % | -49.59 | |||||
| 12-1 Month Momentum % | -68.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.82 | |||||
| Quick Ratio | 0.4 | |||||
| Cash Ratio | 0.07 | |||||
| Days Inventory | 228.48 | |||||
| Days Sales Outstanding | 55.52 | |||||
| Days Payable | 53.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2 | |||||
| Shareholder Yield % | 31.29 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.18 | |||||
| Operating Margin % | -6.33 | |||||
| Net Margin % | -13.18 | |||||
| FCF Margin % | -1.85 | |||||
| ROE % | -18.36 | |||||
| ROA % | -9.44 | |||||
| ROIC % | -5.05 | |||||
| 3-Year ROIIC % | 84.13 | |||||
| ROC (Joel Greenblatt) % | -28.04 | |||||
| ROCE % | -8.38 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 8.06 | |||||
| PS Ratio | 0.3 | |||||
| PB Ratio | 0.45 | |||||
| Price-to-Operating-Cash-Flow | 19.71 | |||||
| EV-to-EBIT | -7.24 | |||||
| EV-to-EBITDA | -22.42 | |||||
| EV-to-Revenue | 0.65 | |||||
| EV-to-FCF | -33.58 | |||||
| Price-to-GF-Value | 0.24 | |||||
| Price-to-Projected-FCF | 0.32 | |||||
| Price-to-Median-PS-Value | 0.25 | |||||
| Earnings Yield (Greenblatt) % | -13.81 | |||||
| FCF Yield % | -6.43 | |||||
| Forward Rate of Return (Yacktman) % | -9.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Harvard Bioscience Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 87.254 | ||
| EPS (TTM) (€) | -0.265 | ||
| Beta | 0.42 | ||
| 3-Year Sharpe Ratio | -0.72 | ||
| 3-Year Sortino Ratio | -0.93 | ||
| Volatility % | 51.72 | ||
| 14-Day RSI | 11.7 | ||
| 14-Day ATR (€) | 0.043465 | ||
| 20-Day SMA (€) | 0.91225 | ||
| 12-1 Month Momentum % | -68.53 | ||
| 52-Week Range (€) | 0.58 - 4.18 | ||
| Shares Outstanding (Mil) | 43.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Harvard Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Harvard Bioscience Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Harvard Bioscience Inc Frequently Asked Questions
What is Harvard Bioscience Inc(FRA:HBI)'s stock price today?
The current price of FRA:HBI is €0.58. The 52 week high of FRA:HBI is €4.18 and 52 week low is €0.58.
When is next earnings date of Harvard Bioscience Inc(FRA:HBI)?
The next earnings date of Harvard Bioscience Inc(FRA:HBI) is 2025-05-07 Est..
Does Harvard Bioscience Inc(FRA:HBI) pay dividends? If so, how much?
Harvard Bioscience Inc(FRA:HBI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers